Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2022 01:00 ET | Source: Addex Therapeutics

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN),...
May 27, 2022 01:00 ET | Source: Addex Therapeutics

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
May 19, 2022 01:00 ET | Source: Addex Therapeutics

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
May 13, 2022 01:00 ET | Source: Addex Therapeutics

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
May 10, 2022 01:00 ET | Source: Addex Therapeutics

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
May 05, 2022 01:00 ET | Source: Addex Therapeutics

Addex Reports Q1 2022 Financial Results

CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase 2b/3 dipraglurant study in dyskinesia...
April 28, 2022 01:00 ET | Source: Addex Therapeutics

Addex to Present at the Swiss Biotech Day 2022

Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
April 25, 2022 01:00 ET | Source: Addex Therapeutics

Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference

Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
April 13, 2022 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a...
April 06, 2022 01:00 ET | Source: Addex Therapeutics

Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders

New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 -...